Colloidal Oatmeal Lotion

Colloidal Oatmeal Lotion

PEP Topic 
Skin Reactions
Description 

Colloidal oatmeal is a product comprising finely ground oats. Oatmeal contains flavonoids and appears to have antioxidant and anti-inflammatory properties that may be beneficial in a variety of dermatologic conditions. Colloidal oatmeal lotion was evaluated in patients with cancer for the prevention and management of skin effects.

Effectiveness Not Established

Research Evidence Summaries

Alexandrescu, D.T., Vaillant, J.G., & Dasanu, C.A. (2006). Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clinical and Experimental Dermatology, 32, 71–74.

doi: 10.1111/j.1365-2230.2006.02285.x
Print

Study Purpose:

To evaluate the effectiveness of colloidal oatmeal lotion (Aveeno®), administered TID for at least seven days.

Sample Characteristics:

  • The study reported on a sample of 10 patients.
  • Patients were receiving epidermal growth factor receptor–inhibitor (EGFRI) and tyrosine-kinase inhibitor (TKI) therapy (e.g., cetuximab, erlotinib, panitumumab, sorafenib) and were experiencing cutaneous reactions.

Setting:

Multiple centers in Washington, DC, and New York, NY

Study Design:

This was an open-label study used to evaluate the rate and quality of response to colloidal oatmeal lotion.

Measurement Instruments/Methods:

Toxicity was graded as follows.

  • Grade 1: asymptomatic, erythematous rash
  • Grade 2: rash plus itching
  • Grade 3: confluent lesions and tenderness
  • Grade 4: deep ulcerations and exfoliative or severe xerosis

Results:

  • Ten of 11 patients were evaluable.
  • Six patients had a complete response and four had a partial response; therefore, the response rate was 100%.
  • Responses occurred from six to 10 days after initiation of colloidal oatmeal lotion.

Conclusions:

Treatment with colloidal oatmeal lotion appeared to be effective in controlling rash associated with EGFRIs and multiple TKIs. This treatment allowed for the continuation of antineoplastic therapy.

Limitations:

  • This was a small, nonrandomized, open-label study.
  • The description of the measurement tool or method used to grade rash symptoms was inadequate; reliability and validity were unclear.

Menu